Why Is CAPRICOR THERAPEUTIC (CAPR) Stock Moving Today?
By the Top Tier Newswire AI Desk · July 29, 2026 at 5:28 AM ET · reviewed against 9 wire stories
CAPRICOR THERAPEUTIC (CAPR) is drawing unusual attention today. Our newswire has captured 9 stories on CAPR across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 47/100).
Why CAPR stock is moving today
CAPR stock is moving sharply lower today, down nearly 66% over the last eight sessions, as growing skepticism about the FDA approval prospects for its drug candidate deramiocel intensifies. Analysts and insiders are raising concerns about the strength of the data supporting the drug’s efficacy in treating Duchenne Muscular Dystrophy cardiomyopathy. The FDA’s upcoming advisory committee meeting has become a focal point, with recent briefing documents casting doubt on the clinical trial analysis plan.
What Happened
Capricor Therapeutics faces mounting pressure as several analysts downgrade the stock and highlight the elevated risk of regulatory rejection. Alliance Global and Roth Capital have both flagged the FDA advisory meeting as a potential hurdle, while B. Riley and Cantor have echoed concerns about the drug’s approval path. The company disclosed that the FDA briefing relies on an outdated analysis plan, further fueling uncertainty. Meanwhile, insider sales by key executives, including CFO Anthony Bergmann and EVP Karen Krasney, have added to investor unease.
Retail traders are showing mixed sentiment, with some on Reddit and Stocktwits expressing bullish conviction despite the sharp selloff. However, the broader market is reacting to the deteriorating fundamentals and regulatory headwinds.
What The Data Shows
Over the past eight trading days, CAPR has fallen from $19.44 to $6.57, a decline of 66.2%. The stock is now trading near the lower end of its 52-week range of $4.30 to $40.37. Unusual options activity has also been observed, with $5.0 million in call premium traded, including a notable $1.4 million print. Insiders have sold a total of $1.5 million in shares over the last 90 days, with no insider purchases recorded. The stock’s beta of 0.42 suggests it is less volatile than the broader market, but recent performance defies that trend.
What To Watch
Investors should closely monitor the FDA advisory committee meeting, the outcome of which could determine the near-term trajectory of CAPR. No earnings date was provided, but coverage breadth and analyst commentary will remain key indicators of market sentiment.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
CAPR · Jul 28 session (5-min) · -4.65% vs prior close · updated 8:49 PM ETAI sentiment, last 36h · averaged over 9 stories · 47/100 neutral
The headlines behind the move
Story flow · 9 stories on the wire, last 36h · hover or tap a dot for the headline
7h agoStocktwits NewsBEARISH 38Product/PR
CAPR Stock Eyes Worst Week Ever After FDA Panel Blow To Deramiocel — Retail Bulls Still See A Path To Approval
Some advisers viewed the upper-limb data more favorably, fueling hopes for a narrower approval focused on that benefit.
10h agoPR NewswireBEARISH 34General
Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Concerning FDA Review And Advisory Committee Meeting - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES, July 29, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR) investors concerning...
11h agoPR NewswireBEARISH 28General
Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR)
Capricor investors lost 60% to 70% after FDA briefing documents challenged the Company's claims that Deramiocel demonstrated statistically significant benefits. NEW YORK, July 29, 2026 /PRNewswire/ -- Capricor (NASDAQ: CAPR) investors were hit with a 60% to 70% drop on July 27, 2026,...
13h agoStocktwits NewsBEARISH 34General
Capricor Faces Make-Or-Break FDA Panel For Duchenne Cell Therapy — Experts And Investors Weigh In
Earlier this week, the FDA questioned how Capricor analyzed results from its late-stage HOPE-3 trial, sending the stock sharply lower and raising doubts about a potential approval.
17h agoStocktwits NewsBULLISH 73Product/PR
Capricor’s DMD Therapy Gets Lancet Backing Ahead Of August FDA Showdown – CEO Says Publication ‘Reinforce Our Confidence’ For Approval
The publication comes ahead of a crucial U.S. Food and Drug Administration advisory committee meeting and the agency’s final approval decision in August.
Capricor Therapeutics ( ($CAPR) ) has issued an announcement. On July 29, 2026, Capricor reported that The Lancet published the final one-year results from its Phas...
20h agoSEC 8-KNEUTRAL 50General
CAPRICOR THERAPEUTICS, INC. (CAPR) files 8-K
Filed: 2026-07-29 AccNo: 0001104659-26-087891 Size: 180 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
20h agoStockTitanBULLISH 63Product/PR
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy | CAPR Stock News
22h agoBusiness InsiderBEARISH 34General
CAPR INVESTIGATION: Capricor Therapeutics Investors Should Contact Block & Leviton About Recovering Their Losses
Boston, Massachusetts--(Newsfile Corp. - July 29, 2026) - Block Leviton is investigating Capricor Therapeutics (NASDAQ: CAPR) for potential securities law violations. Investors who have lost money in...
Frequently asked questions
Why is CAPR stock moving today?
CAPRICOR THERAPEUTIC (CAPR) is drawing unusual attention today. Our newswire has captured 9 stories on CAPR across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 47/100). The most recent driver: "CAPR Stock Eyes Worst Week Ever After FDA Panel Blow To Deramiocel — Retail Bulls Still See A Path To Approval" (Stocktwits News).
Is CAPR a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of CAPR coverage reads 47/100 over 9 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →